DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, Rongsheng E. | ko |
dc.contributor.author | Liu, Tao | ko |
dc.contributor.author | Wang, Ying | ko |
dc.contributor.author | Cao, Yu | ko |
dc.contributor.author | Du, Jintang | ko |
dc.contributor.author | Luo, Xiaozhou | ko |
dc.contributor.author | Deshmukh, Vishal | ko |
dc.contributor.author | Kim, Chan Hyuk | ko |
dc.contributor.author | Lawson, Brian R. | ko |
dc.contributor.author | Tremblay, Matthew S. | ko |
dc.contributor.author | Young, Travis S. | ko |
dc.contributor.author | Kazane, Stephanie A. | ko |
dc.contributor.author | Wang, Feng | ko |
dc.contributor.author | Schultz, Peter G. | ko |
dc.date.accessioned | 2016-07-04T06:01:53Z | - |
dc.date.available | 2016-07-04T06:01:53Z | - |
dc.date.created | 2016-05-14 | - |
dc.date.created | 2016-05-14 | - |
dc.date.created | 2016-05-14 | - |
dc.date.issued | 2015-03 | - |
dc.identifier.citation | JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, v.137, no.9, pp.3229 - 3232 | - |
dc.identifier.issn | 0002-7863 | - |
dc.identifier.uri | http://hdl.handle.net/10203/209125 | - |
dc.description.abstract | We have developed a novel antibody-drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells. The resulting dasatinib-antibody conjugate suppresses T-cell-receptor (TCR)-mediated T-cell activation and cytokine expression with low nM EC50 and has minimal effects on cell viability. This ADC may lead to a new class of selective immunosuppressive drugs with improved safety and extend the ADC strategy to the targeted delivery of kinase inhibitors for indications beyond oncology. | - |
dc.language | English | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | CHEMOKINE RECEPTOR CXCR4 | - |
dc.subject | SRC/ABL KINASE INHIBITOR | - |
dc.subject | HUMAN T-LYMPHOCYTES | - |
dc.subject | IN-VITRO | - |
dc.subject | RATIONAL DESIGN | - |
dc.subject | BREAST-CANCER | - |
dc.subject | CELL-RECEPTOR | - |
dc.subject | DASATINIB | - |
dc.subject | ACTIVATION | - |
dc.subject | BMS-354825 | - |
dc.title | An Immunosuppressive Antibody-Drug Conjugate | - |
dc.type | Article | - |
dc.identifier.wosid | 000351187200020 | - |
dc.identifier.scopusid | 2-s2.0-84924690207 | - |
dc.type.rims | ART | - |
dc.citation.volume | 137 | - |
dc.citation.issue | 9 | - |
dc.citation.beginningpage | 3229 | - |
dc.citation.endingpage | 3232 | - |
dc.citation.publicationname | JOURNAL OF THE AMERICAN CHEMICAL SOCIETY | - |
dc.identifier.doi | 10.1021/jacs.5b00620 | - |
dc.contributor.localauthor | Kim, Chan Hyuk | - |
dc.contributor.nonIdAuthor | Wang, Rongsheng E. | - |
dc.contributor.nonIdAuthor | Liu, Tao | - |
dc.contributor.nonIdAuthor | Wang, Ying | - |
dc.contributor.nonIdAuthor | Cao, Yu | - |
dc.contributor.nonIdAuthor | Du, Jintang | - |
dc.contributor.nonIdAuthor | Luo, Xiaozhou | - |
dc.contributor.nonIdAuthor | Deshmukh, Vishal | - |
dc.contributor.nonIdAuthor | Lawson, Brian R. | - |
dc.contributor.nonIdAuthor | Tremblay, Matthew S. | - |
dc.contributor.nonIdAuthor | Young, Travis S. | - |
dc.contributor.nonIdAuthor | Kazane, Stephanie A. | - |
dc.contributor.nonIdAuthor | Wang, Feng | - |
dc.contributor.nonIdAuthor | Schultz, Peter G. | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | CHEMOKINE RECEPTOR CXCR4 | - |
dc.subject.keywordPlus | SRC/ABL KINASE INHIBITOR | - |
dc.subject.keywordPlus | HUMAN T-LYMPHOCYTES | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | RATIONAL DESIGN | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | CELL-RECEPTOR | - |
dc.subject.keywordPlus | DASATINIB | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | BMS-354825 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.